| Methods |
RCT, 1994‐2000, concealed allocation* |
| Participants |
389 patients randomised, age 65‐90, median 72, gender m/f: 216/173
country: Netherlands, Belgium
stage II‐IV high‐grade NHL, untreated |
| Interventions |
CHOP with G‐CSF versus CHOP without G‐CSF
1. CT:
Cyclophosphamide 750 mg/m², iv, d1
Doxorubicin 50 mg/m², iv, d1
Vincristine 1.4 mg/m², iv, d1
Prednisone 50 mg/m², po, d1‐5
2. G‐CSF 300 µg/day sc, d2‐d11
3. no placebo given
4. no AB prophylaxis given |
| Outcomes |
received dose intensity, severe neutropenia and infections, tumour response, survival, QoL, costs |
| Notes |
supported by the Dutch National Health Council |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
A ‐ Adequate |
